This document contains supplementary in vitro NMR, HPLC, and mass spectrometry data for COX-1 inhibitor 3d and related compounds, with no clinical trial results reported.
Does compound 3d improve in vitro thrombolysis and inhibit platelet aggregation and inflammation in preclinical models of in-stent thrombosis?
Compound 3d is a novel COX-1 inhibitor that demonstrates combined anti-inflammatory and antiplatelet effects in vitro, and synergistically enhances urokinase-mediated thrombolysis.
Twelve benzohydrazide Schiff base derivatives (3a–3l) with systematic variations in the aromatic aldehyde moiety were designed and synthesized to evaluate their anti-inflammatory, antiplatelet, and in vitro antithrombotic activities.
Ma et al. (Thu,) conducted a other in In-stent thrombosis. COX-1 inhibitor 3d combined with catheter-directed thrombolysis was evaluated. This document contains supplementary in vitro NMR, HPLC, and mass spectrometry data for COX-1 inhibitor 3d and related compounds, with no clinical trial results reported.